- Akari Therapeutics (AKTX, Financial) has released a new corporate update video featuring their newly appointed CEO.
- The video shares insights on the company's future strategies and is available on the Akari website.
- Abizer Gaslightwala, a veteran in the biotechnology sector, leads the company's vision for advancing cancer treatment.
Akari Therapeutics (AKTX), a biotechnology firm at the forefront of developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer therapy, has launched a corporate update video featuring Abizer Gaslightwala, their newly appointed President and Chief Executive Officer. The video was released on April 22, 2025, and can be accessed through the Investors section of the company's website at www.akaritx.com.
Abizer Gaslightwala brings extensive experience from the biotechnology and pharmaceutical industries, providing strategic insights and leadership as Akari Therapeutics drives forward with innovation in cancer treatment. Their leading candidate, AKTX-101, targets the TROP2 receptor on cancer cells and promises to address many challenges faced by existing ADC therapies, with a novel payload designed to disrupt RNA splicing in cancer cells.
Investors and stakeholders are encouraged to view the corporate update to gain a deeper understanding of Akari Therapeutics' plans for growth and development under Gaslightwala's leadership.
